ArticleCancer cell international2026
Unraveling the oncogenic and immunomodulatory roles of GINS1: a systematic pan-cancer study.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundGINS1 mediates DNA replication fidelity and cell cycle regulation through its integral role in the GINS complex. However, its comprehensive role across diverse cancer types remains unclear. This study aimed to systematically analyze the critical functions of GINS1 across cancers.
methodsWe utilized pan-cancer and multi-omics datasets and applied survival analysis, immune infiltration assessment, functional enrichment analysis, and genomic alteration profiling to explore.
methodsWe utilized pan-cancer and multi-omics datasets and applied survival analysis, immune infiltration assessment, functional enrichment analysis, and genomic alteration profiling to explore expression patterns, prognostic significance, immune infiltration, genomic alterations, and potential therapeutic relevance of GINS1 across multiple cancers. Ultimately, we evaluated the diagnostic performance of GINS1 in four cancer types and validated its functional role in renal cancer through in vitro assays, including colony formation, CCK-8, EdU, and Transwell, confirming that GINS1 knockdown inhibits cell proliferation and impairs PI3K/AKT pathway activity.
resultsGINS1 was significantly upregulated in 31 cancer types and correlated with poor prognosis in multiple malignancies. GINS1, as a biomarker, is concurrently linked to tumor mutational burden (TMB), microsatellite instability (MSI), and RNA m6A modification across tumor lineages. High GINS1 expression was significantly associated with distinct immune infiltration patterns, characterized by reduced NKT cell signatures and increased Th2 cell enrichment. Functional analysis revealed that GINS1 is involved in cell cycle regulation, DNA replication, and oncogenic signaling pathways (PI3K-Akt, p53, and NF-κB). Notably, survival analysis indicated that GINS1 expression affects the immunotherapy response, predicting poor outcomes in patients receiving anti-PD-1 therapy but an improved response to anti-PD-L1 inhibitors. GINS1 exhibited strong diagnostic value in KIRP, LIHC, PAAD, and SARC. In renal cancer, functional assays confirmed that GINS1 knockdown significantly suppressed cell proliferation, migration, and invasion, and attenuated PI3K/AKT signaling activity.
conclusionGINS1 serves as a viable prognostic indicator and target for therapeutic intervention, influencing both tumor progression and immune regulation. Targeting GINS1 may provide new therapeutic insights for cancer management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.